GBT (Global Blood Therapeutics) (GBT) stock price, revenue, and financials

GBT (Global Blood Therapeutics) market cap is $1.9 b, and annual revenue was $123.8 m in FY 2020

$1.9 B

GBT Mkt cap, 15-Oct-2021

$123.8 M

GBT (Global Blood Therapeutics) Revenue FY, 2020
GBT (Global Blood Therapeutics) Gross profit (FY, 2020)121.8 M
GBT (Global Blood Therapeutics) Gross profit margin (FY, 2020), %98.4%
GBT (Global Blood Therapeutics) Net income (FY, 2020)-247.6 M
GBT (Global Blood Therapeutics) EBIT (FY, 2020)-243.2 M
GBT (Global Blood Therapeutics) Cash, 31-Dec-2020494.8 M
GBT (Global Blood Therapeutics) EV1.8 B
Get notified regarding key financial metrics and revenue changes at GBT (Global Blood Therapeutics)Learn more
Banner background

GBT (Global Blood Therapeutics) Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

2.1m123.8m

Cost of goods sold

48.0k2.0m

Gross profit

2.1m121.8m

Gross profit Margin, %

98%98%

R&D expense

36.7m61.2m87.8m131.3m174.6m155.1m

General and administrative expense

9.7m21.9m31.4m51.4m117.1m210.9m

Operating expense total

46.3m83.1m119.2m182.7m283.3m365.0m

EBIT

(46.4m)(83.1m)(119.2m)(182.7m)(281.3m)(243.2m)

EBIT margin, %

(13344%)(196%)

Interest expense

2.6m8.6m14.7m

Interest income

33.0k

Pre tax profit

(82.5m)(117.0m)(174.2m)(266.8m)(247.6m)

Income tax expense

Net Income

(46.4m)(82.5m)(117.0m)(174.2m)(266.8m)(247.6m)

GBT (Global Blood Therapeutics) Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

148.5m92.1m198.3m275.4m302.2m494.8m

Accounts Receivable

2.1m2.6m17.5m

Prepaid Expenses

3.8m6.3m4.7m949.0k

Inventories

1.3m40.2m

Current Assets

150.8m149.8m324.3m485.8m628.0m632.2m

PP&E

2.1m2.4m16.6m15.0m27.1m37.9m

Total Assets

153.1m202.4m356.7m617.6m796.1m724.0m

Accounts Payable

3.4m4.3m7.2m6.0m10.6m19.1m

Short-term debt

4.8m

Current Liabilities

10.7m15.5m26.3m33.8m71.5m79.0m

Long-term debt

145.9m378.0m

Total Debt

145.9m382.8m

Total Liabilities

16.1m37.9m44.8m217.4m307.8m

Common Stock

46.0k56.0k61.0k62.0k

Additional Paid-in Capital

239.2m367.4m617.1m1.0b1.3b1.4b

Retained Earnings

(98.5m)(180.9m)(298.0m)(472.1m)(738.9m)(986.5m)

Total Equity

140.8m186.3m318.8m572.8m578.7m416.2m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.4 x1.7 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

40.6m158.5m134.0m231.9m217.8m135.7m93.7m84.1m455.6m342.1m194.9m156.8m338.5m267.6m315.5m384.7m418.4m

Accounts Receivable

4.6m12.5m14.1m

Prepaid Expenses

419.0k1.6m1.9m1.6m1.7m4.0m5.0m10.4m10.3m7.1m9.0m8.2m8.2m12.7m14.1m13.5m14.8m

Inventories

14.9m27.3m33.8m

Current Assets

42.4m160.7m136.5m234.1m221.3m248.3m234.9m229.8m553.9m469.5m392.2m465.5m666.8m615.8m564.5m594.0m594.7m

PP&E

2.2m2.2m2.3m2.6m2.6m2.4m5.2m13.2m17.4m17.1m16.7m13.1m12.3m14.3m37.3m39.7m38.7m

Total Assets

44.7m163.0m139.0m236.8m224.0m317.7m301.9m284.1m573.4m539.2m510.4m613.1m768.8m727.3m741.1m721.7m691.3m

Accounts Payable

1.5m1.4m4.3m4.8m3.0m3.1m5.0m3.4m7.4m3.4m5.0m7.3m6.8m7.1m13.7m5.7m7.9m

Short-term debt

4.6m

Current Liabilities

5.2m6.6m11.5m13.2m13.2m14.7m17.1m16.4m24.0m21.3m26.9m32.1m39.7m41.2m62.2m69.4m77.9m

Long-term debt

24.4m24.0m23.7m155.3m155.7m154.3m

Total Debt

24.4m24.0m23.7m155.3m155.7m159.0m

Total Liabilities

6.8m8.2m12.8m14.4m13.9m15.2m20.2m25.8m35.6m32.7m38.2m56.5m64.6m69.3m217.6m225.9m233.6m

Common Stock

3.0k29.0k30.0k36.0k37.0k43.0k43.0k43.0k52.0k52.0k52.0k56.0k60.0k60.0k61.0k61.0k61.0k

Preferred Stock

Additional Paid-in Capital

237.7m241.2m355.1m363.8m506.9m510.1m515.1m877.6m886.6m895.5m1.1b1.3b1.3b1.3b1.4b1.4b

Retained Earnings

(67.7m)(82.9m)(115.1m)(132.7m)(153.7m)(204.3m)(228.1m)(256.7m)(339.5m)(379.9m)(422.9m)(521.1m)(578.4m)(642.9m)(811.9m)(864.8m)(924.7m)

Total Equity

(67.7m)154.8m126.1m222.4m210.1m302.5m281.7m258.3m537.8m506.6m472.2m556.5m704.2m658.1m523.6m495.8m457.7m

Financial Leverage

-0.7 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.4 x1.5 x1.5 x

GBT (Global Blood Therapeutics) Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(46.4m)(82.5m)(117.0m)(174.2m)(266.8m)(247.6m)

Depreciation and Amortization

873.0k1.2m1.7m4.6m8.6m8.3m

Accounts Receivable

(2.6m)(14.9m)

Inventories

(1.3m)(36.8m)

Accounts Payable

2.7m1.1m2.8m(1.3m)4.5m8.4m

Cash From Operating Activities

(30.9m)(67.7m)(93.0m)(135.4m)(194.4m)(211.9m)

Purchases of PP&E

(993.0k)(1.4m)(3.1m)(4.8m)(3.5m)(8.8m)

Cash From Investing Activities

(993.0k)(106.9m)(35.9m)(184.2m)(76.9m)317.3m

Dividends Paid

Cash From Financing Activities

128.3m118.1m235.2m397.9m298.2m87.1m

Net Change in Cash

96.4m106.3m78.4m26.9m192.6m

Interest Paid

6.3m

GBT (Global Blood Therapeutics) Ratios

USDQ2, 2015

Financial Leverage

-0.7 x

GBT (Global Blood Therapeutics) Employee Rating

4.319 votes
Culture & Values
4.7
Work/Life Balance
4.7
Senior Management
4.7
Salary & Benefits
4.5
Career Opportunities
4.4
Source